Press release
Generic Solid Dosage Forms Maintain their Rapid Rate of Expansion
(Amherst, NH) – Generic drugs are re-shaping the pharmaceutical industry, and the pace of activity shows no signs of slowing. Nowhere is the rate of change happening more quickly than in solid dosage forms. Because of the relatively low barriers to entry, generic solid dosage forms – better known as tablets and capsules – are outstripping all other drug categories in terms of market authorization approvals. In the year 2000, 142 applications for generic solid dosage forms were approved by the FDA. In 2015 that number was 755.This segment is a rapidly evolving and highly unpredictable environment that has been presenting challenges to decision makers attempting to map strategies for success. There are currently 597 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These 597 APIs account for 4,229 approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of 9,687 unique tablet and capsule products. These products are marketed and supplied by more than 800 companies.
Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.
In terms of therapeutic classes, neurology, cardiology and anti-infectives including antimicrobial agents are the most competitive segments, representing more than half of all marketed generic tablet and capsule products on a unique product basis.
Generic solid dosage forms are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Generic Solid Dosage Forms: Products, Markets, Players and Outlook analyzes generic tablet and capsule products and the indications and therapeutic classes in which they compete. The report includes analysis of competitive factors, ANDA filing strategies, market growth trends and strategic and economic factors, and provides assessments of the market presence of sector participants.
More information is available at http://www.greystoneassociates.org
Source: Greystone Research Associates
About Greystone
Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Contact:
Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generic Solid Dosage Forms Maintain their Rapid Rate of Expansion here
News-ID: 383560 • Views: …
More Releases from Greystone Research Associates
Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration…
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors.
A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when…
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population.
To fully address the unmet need these technologies…
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from…
More Releases for Generic
Generic Injectables Market growth is attributed to the increasing demand for Onc …
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital…
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market
A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs.
The global generic drugs market is driven by the rise of…
Generic Wellness Offers Special Discount on Generic Xenical for Fat Reduction !
This week a special offer is introduced by Generic Wellness for weight loss treatment with an oral drug called generic Xenical. The drug is an excellent weight loss treatment for all men and women above the age of 12. People who have taken this drug for weight loss have actually experienced the benefits like reduction of unwanted fat in the body.
This is possible with generic Xenical because of the…
Generic Drugs Market Trends 2025
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017…
Generic Drugs Market - Global Competitive Analysis
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017…
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 …
Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by…
